Sterile Filtered White lyophilized (freeze-dried) powder.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. - 12 months from date of receipt, -20 to -70 °C as supplied. - 1 month, 2 to 8 °C under sterile conditions after reconstitution. - 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Formulation
Lyophilized from a 0.2 μm filtered concentrated solution in 10 mM Sodium Citrate, pH 3.0.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
Biological Activity
Fully biologically active when compared to standard. The ED50 as determined by its ability to inhibit IGF-II induced proliferation of MCF-7 cells is less than 0.4 μg/ml, corresponding to a specific activity of > 2500 IU/mg in the presence of 15 ng/ml of rHuIGF-II.
Shipping Condition
Gel pack.
Handling
Centrifuge the vial prior to opening.
Usage
For Research Use Only! Not to be used in humans.
Quality Control
Quality Control & DataSheet
View current batch:
Purity > 96 % by SDS-PAGE and HPLC analyses. Endotoxin: Less than 0.1 EU/μg of rHuIGF-BP5 as determined by LAL method.